Recruiting
An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany - CA209-1210
Mis à jour:
17 avril, 2024
|
ClinicalTrials.gov
Sexe(s)
Tranche d’âge
Emplacement(s)
Recruiting
Inclusion Criteria: - Aged 18 years or older - Diagnosis of non-metastatic non-small cell lung cancer with tumor Programmed death-ligand 1 (PD-L1) expression level of 1% or more (tumor proportion score (TPS); according to label approved in the European Union) - Decision to initiate a neoadjuvant treatment with nivolumab plus platinum-based chemotherapy for treatment of non-small cell lung cancer according to current Summary of product characteristics and independent of the study - Willing to complete patient-reported outcome questionnaires and sufficient understanding of the German language - Signed written informed consent - Other criteria according to current Summary of product characteristics Exclusion Criteria: - Current primary diagnosis of cancer other than non-small cell lung cancer that requires systemic or other treatment - Other contraindications according to current Summary of product characteristics
Nous vous recommandons fortement de contacter BMS pour signaler les effets secondaires (événements indésirables).
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici.
Signaler des effets secondaires (effets indésirables) ou des plaintes concernant la qualité du produit: Informations médicales